UBS Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-21,311
| Closed | -$392K | – | 9900 |
|
|
2020
Q4 | $392K | Sell |
21,311
-2,715
| -11% | -$49.5K | ﹤0.01% | 4798 |
|
|
2020
Q3 | $441K | Buy |
24,026
+16,859
| +235% | +$283K | ﹤0.01% | 4293 |
|
|
2020
Q2 | $107K | Sell |
7,167
-1,493
| -17% | -$21.3K | ﹤0.01% | 5250 |
|
|
2020
Q1 | $137K | Sell |
8,660
-6,526
| -43% | -$105K | ﹤0.01% | 5025 |
|
|
2019
Q4 | $247K | Buy |
15,186
+5,024
| +49% | +$83.8K | ﹤0.01% | 5450 |
|
|
2019
Q3 | $151K | Buy |
10,162
+6,370
| +168% | +$85.9K | ﹤0.01% | 5465 |
|
|
2019
Q2 | $63K | Buy |
3,792
+3,160
| +500% | +$51.6K | ﹤0.01% | 5724 |
|
|
2019
Q1 | $11K | Sell |
632
-3,654
| -85% | -$66.3K | ﹤0.01% | 6782 |
|
|
2018
Q4 | $76K | Buy |
4,286
+1,361
| +47% | +$23.1K | ﹤0.01% | 5779 |
|
|
2018
Q3 | $53K | Buy |
2,925
+879
| +43% | +$18K | ﹤0.01% | 6121 |
|
|
2018
Q2 | $40K | Buy |
+2,046
| New | +$38.3K | ﹤0.01% | 6177 |
|
|
2017
Q4 | – | Sell |
-1,507
| Closed | -$16K | – | 8225 |
|
|
2017
Q3 | $16K | Buy |
1,507
+1,376
| +1,050% | +$13K | ﹤0.01% | 6621 |
|
|
2017
Q2 | $1K | Sell |
131
-1,208
| -90% | -$10.6K | ﹤0.01% | 7553 |
|
|
2017
Q1 | $16K | Sell |
1,339
-2,145
| -62% | -$26.1K | ﹤0.01% | 6327 |
|
|
2016
Q4 | $46K | Buy |
3,484
+140
| +4% | +$1.87K | ﹤0.01% | 5893 |
|
|
2016
Q3 | $48K | Buy |
+3,344
| New | +$47.5K | ﹤0.01% | 5559 |
|
|
2015
Q4 | – | Sell |
-1,502
| Closed | -$25K | – | 8676 |
|
|
2015
Q3 | $25K | Sell |
1,502
-2,701
| -64% | -$67.2K | ﹤0.01% | 6493 |
|
|
2015
Q2 | $158K | Sell |
4,203
-12,497
| -75% | -$403K | ﹤0.01% | 5072 |
|
|
2015
Q1 | $525K | Buy |
16,700
+14,037
| +527% | +$379K | ﹤0.01% | 4106 |
|
|
2014
Q4 | $34K | Buy |
+2,663
| New | +$40.8K | ﹤0.01% | 6979 |
|
UBS Group's CBMG Position: Q1 2021 in Review
UBS Group sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 21,311 shares — an estimated $392K sold.
UBS Group first reported a position in CBMG in Q4 2014 and held it in 20 quarters. The position peaked at $525K in Q1 2015. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- UBS Group reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- UBS Group sold 21,311 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $392K.
- UBS Group first reported a position in Cellular Biomedicine Group, Inc. in Q4 2014 and held it in 20 quarters.
- UBS Group's Cellular Biomedicine Group, Inc. position peaked at $525K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.